CMC Development and Strategy is a Keystone of Advanced Immunotherapy Development
May 3, 2022
José Manuel Otero, PhD, Chief Technology Officer at Turnstone, will discuss the distinguishing features of bioprocesses used in production of unique viral immunotherapies and tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancer treatment. These treatments are currently in early-stage clinical development and have progressed from the development laboratory to GMP manufacturing, with continued investment towards eventual commercialization.
ABOUT THE SPEAKERS
José Manuel Otero, PhD – Dr. Otero is the Chief Technology Officer and heads bioprocess development, manufacturing, and CMC at Turnstone, across both viral and cell-based therapies, bringing with him 20 years of industry experience in vaccines and complex biologics. He joined Turnstone from Seres Therapeutics, Inc., where he was Vice President of Bioprocess Development and Manufacturing. Dr. Otero oversaw expansion of the group and was the team leader for the first synthetic microbiome therapy to enter clinical studies in the U.S. Dr. Otero started his career at Merck & Co., Inc., where he was Head of Fermentation Development before becoming a Director of Engineering to support multiple commercial vaccine franchises. He is a member of the Connecticut Academy of Science and Engineering, earned a Ph.D. in chemical and biological engineering from Chalmers University of Technology, and an M.Eng. in biomedical engineering and a B.S. in chemical engineering from the Massachusetts Institute of Technology.